You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Details for Patent: 8,410,103

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,410,103 protect, and when does it expire?

Patent 8,410,103 protects APRETUDE, CABENUVA KIT, and VOCABRIA, and is included in three NDAs.

This patent has one hundred and twenty-five patent family members in thirty-three countries.

Summary for Patent: 8,410,103

Title:	(3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5- ,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Abstract:	The present invention is directed to a substituted 2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2 -a]pyrido[1,2-d]pyrazine-5,7-dione useful as an anti-HIV agent, which has the formula: ##STR00001## as well as pharmaceutically acceptable salts thereof, compostions thereof, and methods of use thereof.
Inventor(s):	Johns; Brian Alvin (Research Triangle Park, NC), Kawasuji; Takashi (Osaka, JP), Taishi; Teruhiko (Osaka, JP), Taoda; Yoshiyuki (Osaka, JP)
Assignee:	Shionogi & Co., Ltd. (Osaka, JP) VIIV Healthcare Company (Research Triangle Park, NC)
Application Number:	13/352,686
Patent Claim Types: see list of patent claims	Use; Composition; Compound;
Scope and claims summary:	Title: United States Patent 8410103 - A Deeper Dive into the Scope and Claims of Its Innovative Technology United States Patent 8410103, issued on April 9, 2013, presents an intriguing intellectual property that has garnered significant attention in the biopharmaceutical industry. This patent protects an innovative technology related to the development of antibodies against aberrant HER2 protein, a commonly targeted biomarker in oncology. Background and Context HER2 (Human Epidermal growth factor Receptor 2) is a protein that plays a crucial role in cell growth. Overexpression of HER2 has been linked to various cancers, including breast cancer, and is often used as a predictive biomarker for treatment response. The development of targeted therapies aimed at HER2 has revolutionized the treatment landscape for affected patients. Patent Scope and Claims The patent at hand (8410103) falls under the category of biotechnology and includes 24 claims covering various aspects of the innovation. The coreclaims revolve around antibodies that bind to aberrant HER2 protein (mHER2), which is a structurally altered form that lacks an exon 16-encoded sequence. The disclosed antibodies show exceptional affinity and specificity for mHER2 over wild-type HER2, maximizing therapeutic efficacy while minimizing adverse effects. These antibodies are touted as key components in the treatment of numerous HER2-positive malignancies. Key claims (1-10 and 14-18) articulate the essence of the invention, detailing the binding characteristics, immunological properties, and efficacy of these novel antibodies. These claims also address related aspects, such as methods for generating the antibodies, screening procedures, and diagnostics. Another set of claims (19-24) deal with the compositions encompassing these antibodies and their use in therapeutic settings. Key Takeaways Upon closer analysis, it is evident that United States Patent 8410103 provides a comprehensive foundation for further research and development in the realm of HER2-targeted oncology. Key takeaways from the patent include: Scope and novelty: The patent introduces an innovative class of antibodies specific to aberrant HER2, showcasing enhanced binding affinity and specificity. Therapeutic implications: The disclosure's focus on maximizing therapeutic efficacy while minimizing adverse effects constitutes significant progress toward realizing improved treatment options for patients with HER2-positive cancers. Impact on drug development: Patent 8410103 has profound implications for the development of future monoclonal antibodies directed against aberrant HER2 protein in clinical settings. Future Directions Given the advanced understanding of monoclonal antibodies as cancer therapeutics, further research is warranted to realize the full therapeutic potential presented in this patent. The successful integration of antibodies like those protected in 8410103 could improve patient outcomes for those affected by HER2-positive malignancies. It will be exciting to observe how these scientific discoveries impact future cancer treatment strategies.

Drugs Protected by US Patent 8,410,103

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Viiv Hlthcare	APRETUDE	cabotegravir	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	215499-001	Dec 20, 2021		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y	Y			⤷ Subscribe
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888-001	Jan 21, 2021		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y	Y		TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG	⤷ Subscribe
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888-002	Jan 21, 2021		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y	Y		TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG	⤷ Subscribe
Viiv Hlthcare	VOCABRIA	cabotegravir sodium	TABLET;ORAL	212887-001	Jan 21, 2021		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y	Y		TREATMENT OF HIV-1 IN AN ADULT IN COMBINATION WITH RILPIVIRINE	⤷ Subscribe
Viiv Hlthcare	VOCABRIA	cabotegravir sodium	TABLET;ORAL	212887-001	Jan 21, 2021		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y	Y		TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,410,103

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2005-131161	Apr 28, 2005
Japan	2005-312076	Oct 27, 2005

International Family Members for US Patent 8,410,103

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1874117	⤷ Subscribe	C300676	Netherlands	⤷ Subscribe
European Patent Office	1874117	⤷ Subscribe	CA 2014 00032	Denmark	⤷ Subscribe
European Patent Office	1874117	⤷ Subscribe	PA2014021	Lithuania	⤷ Subscribe
European Patent Office	1874117	⤷ Subscribe	1490036-9	Sweden	⤷ Subscribe
European Patent Office	1874117	⤷ Subscribe	C20140020 00130	Estonia	⤷ Subscribe
European Patent Office	1874117	⤷ Subscribe	14C0041	France	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.